$55B
Annual healthcare spend
6.5%
Of GDP
35%
Private-participation target
$20B+
Unlocked for private capex
Sub-sectors
Hospitals & specialty centers
Privatization of MoH facilities is underway. Oncology, cardiology, IVF, rehab and long-term care are priority specialties.
Pharmaceuticals
$6.5B market, 70% imported. API and finished-dose localization carries 20–30% procurement preference.
Medical devices
$2.8B today, $4.2B by 2030. SFDA fast-track for Class A/B local manufacturers.
Digital health
Telemedicine, EHR, RPM, AI diagnostics. SDAIA + MoH joint regulatory sandbox active since 2023.
Lab networks & diagnostics
Genomics, molecular diagnostics, decentralized labs. SCFHS accreditation pathway.
Biotech & vaccines
SPIMACO, Lifera (PIF), KAIMRC – co-investment opportunities for cell & gene therapy.
Regulatory stack
- MISA investment license (4–6 weeks)
- Commercial registration + Chamber of Commerce
- MoH facility classification & license (12–20 weeks)
- SFDA product registration (8–16 weeks; 6–12 with pre-validation)
- SCFHS accreditation for clinical staff
- NPHIES integration for insurance claims
Incentives
- Local-content procurement preference up to 30% for MoH and NUPCO tenders.
- Customs exemption on medical equipment and APIs.
- R&D tax credit (RDIA) up to 50% on qualified clinical research.
- Subsidized land in Sudair Pharma City and KAEC Health Cluster.
The All Care sovereign-localisation moat
Zero-greenfield JV model
All Care absorbs the CAPEX (facilities, warehousing, logistics). You inject IP and know-how. Launch within 90 days instead of the typical 24-month greenfield buildout.
Anti-dumping shield – up to 70%
Localised products trigger anti-dumping protections of up to 70% tariffs on imported alternatives, materially compressing competitor margin.
Procurement preference (LCGPA)
"Saudi-Made" status locks in mandatory bid-preference in NUPCO and giga-project tenders – effectively sidelining non-localised global competitors.
Operational reality
37+ managed healthcare facilities, 14,000+ medical-device SKUs (ISO 13485 / CE / SFDA / FDA), 4,000+ specialised nursing staff and 12 clinics + 20 pharmacies in network.
The asset-docking framework
We do not simply distribute – we co-invest. The All Care JV framework integrates your IP, patents and clinical-trial assets (up to $8M valued as in-kind contribution) into a 50/50 governance structure engineered for a 3-year IPO / PIF exit horizon.